-
Results from a Phase III study in men ages 16 to 26 indicate that the human papillomavirus (HPV) vaccine Gardasil (Merck & Co.) prevented 90% of external genital lesions caused by types 6, 11, 16, and 18 of HPV.
-
How many of your patients rely on vasectomy for contraception? About 500,000 vasectomies are performed each year in the United States; about one out of six U.S. men over age 35 has been vasectomized, with prevalence increasing with education and income.
-
Two years after the government implemented routine HIV testing for all patients ages 13-64 without regard to risk, public health officials say improvements have been made, yet still one in five people infected with the AIDS virus is unaware of his/her status.
-
The risk of recurrent venous thromboembolism (VTE) during extended anticoagulant therapy for thrombophilia remains poorly defined. Investigators analyzed 661 patients with idiopathic VTE who had been randomized to extended prophylaxis after three months of initial anticoagulation using either low intensity (INR 1.5-1.9) or standard intensity (INR 2.0-3.0) anticoagulation.
-
The role of bisphosphonates in the treatment and prevention of bone metastases remains incompletely characterized. In the current report, Diel et al detail long-term survival data on patients with known microscopic bone disease more than eight years after adjuvant treatment with clodronate.
-
Thalidomide-rituximab was administered to 25 symptomatic patients (20 previously untreated) with Waldenstrom macroglobulinemia. The overall response rate was 72%, and the median time-to-progression for responders was 38 months.
-
Among patients who undergo screening and are diagnosed with prostate cancer, there is a dichotomy between those who are diagnosed after their initial screening (prevalent cases) and those who have cancer detected after subsequent screenings (incident cases).
-
A new regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT]) was tested in a phase II trial in 54 patients with gastric or gastro-esophageal cancer. Response rates were comparable, or perhaps even a little better than those published for other combinations; the toxicity profile appears favorable.
-
-
The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
